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Editorial on the Research Topic
Novel Approaches to the Neuropharmacology of Mood Disorders
These are exciting times for research on the pharmacology of mood disorders. The “omics” revolutions, 
the development of noninvasive neuroimaging techniques, the definition of biomarkers, and studies 
in animal models have all partially redefined the field and contributed to the boom in research articles 
focusing on novel approaches to the neuropharmacology of both major depressive disorder and bipolar 
disorder. Recent studies on the fast antidepressant effects of ketamine have also brought this topic to the 
mainline press, where the effectiveness (or lack of) of psychopharmacological drugs targeting mood 
disorders has been discussed multiple times.
Although management of mood disorders does not solely imply the use of a psychopharmacological 
approach, the prescription of antidepressants and mood stabilizers represents the mainstay of the 
standard of care for the treatment of mood disorders.
This research topic is a collection of reviews and original research articles that focus on the study 
of mechanistic approaches to decipher specific actions of currently used drugs, and on evaluating 
possible therapeutic interventions by acting on novel pharmacological targets and analyzing signal 
transduction pathways that may be involved in mediating the effects of drugs acting on those targets. 
The topic also collects a series of articles devoted to the analysis of different biomarkers that could be 
used to predict the therapeutic efficacy of specific pharmacologic treatments particularly in the case 
of treatment-resistant depression.
The effects of inflammatory processes in mood and anxiety disorders and the possible efficacy of 
current and novel psychopharmacological approaches in tackling mood disorders symptoms by acting 
on peripheral and/or central inflammatory events are evaluated in three contributions to the present 
topic: First, Zhang et al. study the effects of the dual serotonin and norepinephrine reuptake inhibitor 
venlafaxine in reversing the deficits in cognition and depressive-like behavior induced by cuprisone 
treatment in rodents, by attenuating demyelination and neuroinflammation. Then, review by Brymer 
et al. examines the putative antidepressant mechanisms of anti-inflammatory drugs that target tumor 
necrosis factor alpha (TNFα) and explains how both peripheral and central anti-inflammatory 
mechanisms may be operative in fostering the antidepressant effects of these drugs. Finally, Nisbett 
and Pinna contribute an opinion article on how fostering the function of the peroxisome proliferator-
activated receptor alpha (PPARα) brings about a decrease in proinflammatory cytokines, and focus 
on the effects of cannabinoids on PPARα in the context of posttraumatic stress disorder (PTSD). 
These three contributions emphasize how the anti-inflammatory effects of current antidepressants, 
like venlafaxine, or of anti-inflammatory drugs, like etanercept [an antagonist of tumor necrosis 
factor alpha (TNFα)], that have been shown to exert antidepressant effects, or those related to 
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novel targets, like PPARα, may be essential for their therapeutic 
effects on mood disorders and underline how understanding the 
mechanistic implications of inflammatory processes in mood 
disorders may give some clues both to better understand the 
neurobiology of these disorders and to develop novel and more 
efficacious drugs.
Another two contributions center on the analysis of circuit 
and/or molecular mechanisms that can relate to the therapeutic 
actions of psychopharmacological interventions on mood and 
anxiety disorders: An original research article by Zhang et 
al. describes how overexpression in the hippocampal dentate 
gyrus of the translocator protein of 18 kDa results in anxiolytic 
effects in an animal model of PTSD and discusses the roles of 
hippocampal neurogenesis in the formation and maintenance 
of emotional memories that also pertain to the neurobiology of 
major depression and bipolar disorder, as it has been proposed 
in multiple occasions that rescuing of hippocampal neurogenesis 
may be a mechanism by which antidepressant drugs may reverse 
some key symptoms in depression. A second original report, 
authored by Park et al., investigates the actions of liraglutide 
(a  glucogen-like peptide 1 receptor agonist) on mammalian target 
of rapamycin (mTOR)-mediated signal transduction pathways 
and on α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic  acid 
(AMPA) receptor activity in hippocampal cell cultures 
treated with dexamethasone, and its impact on brain-derived 
neurotrophic factor (BDNF) expression, dendritic outgrowth, 
and spine formation, which results of clear interest when 
considering that the fast antidepressant actions of ketamine 
appear to be based on its effects on all these factors.
A review by Senese et al. recapitulates their results on the direct 
effects of antidepressant drugs on regulating specific components 
of G-protein coupled receptors systems, particularly their effects on 
reversing the increase in G protein coupled receptor (GPCR) subunit 
localization and clustering into lipid-raft microdomains observed 
in depression, which they propose are essential for the elucidation 
of the antidepressant effects of current antidepressant drugs. 
Interestingly, an original report by Romay-Tallon et al. also analyzes 
the clustering of GPCRs and other proteins in the plasma membrane 
of lymphocytes in the repeated-corticosterone model of depression, 
and shows how analysis of this clustering patterns resembles those 
observed in depression patients and could be considered as 
putative biomarkers of therapeutic efficacy in major depression, 
an aspect that is further discussed and analyzed in a review 
article by Caruncho et al. These three contributions thereby 
point toward the importance of the patterns on membrane proteins 
distribution within specific membrane domains as putative key issues 
in the neurobiology of depression, and foster the design of additional 
studies on membrane protein clustering not only to develop novel 
biomarkers but also as potential drug targets.
The last two contributions to the topic describe original research 
on biomarkers of therapeutic efficacy for treatment-resistant 
depression: Veldic et al. describe a pharmacogenomic approach 
to the analysis of cytochrome P450 2C19 variants in relation to 
their metabolizer phenotype in treatment-resistant depression and 
evaluate the implications of their results in terms of differential 
diagnosis between major depression and bipolar disorder, as well as 
their implications for pharmacological therapeutics in depression. 
Finally, Shalbaf et al. evaluate how non-linear entropy analysis of 
electroencephalography (EEG) can be developed as a biomarker to 
predict the therapeutic response to repetitive transcranial magnetic 
evaluation in treatment-resistant depression. Their results indicate 
the interest of additional EEG studies to validate this approach 
and thereby contribute to a better management of the use of 
nonpharmacological therapeutic strategies for treatment-resistant 
depression.
Overall, the contributions to this topic present a wide-scope and 
multidisciplinary approach that is essential when evaluating novel 
pharmacological strategies for the treatment of mood disorders.
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